Replies to post #122093 on Biotech Values

[$$$eeker]

I'll try to make this simple so you can understand. I WAS IN FCSC TO MAKE MONEY AND I DID MAKE MONEY. END OF STORY!
You still don't get it and never will because your head is stuck and you know where. When you hear that popping sound you'll know it is no longer stuck. LOL on the way to the bank :)

[jessellivermore]

Re FCSC...

Could not agree with Dew more...

This product requires preparation on the part of the doctor which is time consuming, expensive, and aggrevating...And the end product is inferior to fat transfer which is currently the hottest thing in cosmetic surgey..As a Plastic Surgeon, I can not immagine using this product...

":>) JL

[DewDiligence]

FCSC is getting pounded today, which is hardly a surprise when a pump & dump stock enters the dump phase.

I’ll be astonished if laViv ever generates more than token sales, and profitability is out of the question. In all likelihood, FCSC will end up filing for bankruptcy—again.

p.s. Has anyone heard from ronpopeil today?

[DewDiligence]

Oleptro salesforce cut in half:

http://finance.yahoo.com/news/Labopharm-Announces-Reduction-prnews-1503621523.html?x=0&.v=1

This drug is useless and docs know it, so it’s silly to waste money on sales reps.

[DewDiligence]

FCSC—Elimer Piros of Rodman forecasts $1B of peak sales for laViv, but I’ll be shocked if laViv ever sells more than 2% of that. I mention this for all of the devoted Rodman fans on this board :- )

p.s. FCSC is down 22% since obtaining FDA approval Wednesday morning.

[DewDiligence]

FCSC 3-year look-back—the FDA approved Laviv (the company’s only approved product) on 6/22/11:

#msg-64507902

Since 6/22/11, the (split-adjusted) share price is down 86%.

Moral: Regulatory approval doesn’t mean much is there is no material demand for a product.